Eissa LA, Gad LS, Rabie AM, El-Gayar AM

Language: Spanish
References: 69
Page: 235-244
PDF size: 170.51 Kb.

Text Extraction

Thrombocytopenia and oxidative stress are the most frequent problems in patients with chronic liver diseases as viral cirrhosis and schistosomiasis. So, this study aimed to evaluate the role of thrombopoietin (TPO) on the occurrence of thrombocytopenia and in differentiation between these diseases. It also aimed to investigate the relation between TPO, oxidative stress and antioxidant status in these two types of chronic liver disease. So, We measured serum TPO level, lipid peroxide (MDA) and serum total antioxidant activity (TAO) in 40 patients with cirrhosis caused by hepatitis C virus and 37 patients with schistosomiasis from The Specialized Medical Hospital, Mansoura University. Results: Both serum TPO level and serum TAO activity were significantly lower (p ‹ 0.05) in thrombocytopenic patients with viral cirrhosis when compared to both non thrombocytopenic and control groups. In contrast, TPO level was within the normal range in the patients with scistosomiasis either thrombocytopenic or not. while serum TAO activity was significantly lower (p ‹ 0.05) in both thrombocytopenic and non thrombocytopenic patients with schistosomiasis in comparison to control subjects with no significant difference between these two subgroups. Serum MDA concentration was increased significantly (p ‹ 0.05) in all diseased groups when compared to controls with significant increase in thrombocytopenic patients as compared to non thrombocytopenic. Conclusion: TPO hypoproduction played a role in the pathogenesis and treatment of viral cirrhosis associated with thrombocytopenia. Also, total antioxidant activity and MDA are useful markers for monitoring patients with these chronic liver diseases.

REFERENCES

1. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, Ragone E, Durante Mangoni E, Ruggiero G. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. British Journal of Hematology 2001; 113: 590-595.

2. Aref S, Mabed M, Selim T, Goda T, Khafagy N. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 2004; (5-6): 351-356.

3. Bandara P, George J, McCaughan G, Naidoo D, Lux O, Salonikas C, Kench J, Byth K, Farrell GC. Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int 2005; 25(3): 518-26.

4. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. The American Journal of Gastroenterology 2000; 95(10): 2936-2939.

5. Cardin R, D’Errico A, Fiorentino M, Cecchetto A, Naccarato R, Farinati F. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. Alcohol 2002; 37(1): 43-8.

6. Chaudhary AK, Nokubo M, Reddy GR, Yeola SN, Morrow JD, Blair IA, Marnett LJ. Detection of endogenous malondialdehydedeoxyguanosine adducts in human liver. Science 1994; 265(5178): 1580-1582.

7. Chu CW, Hwang SJ, Lu RH, Lai CR, Luo JC, Wang YJ, Chang FY, Lee SD. Clinical significance of the changes of platelet counts and serum thrombopoietin levels in chronic hepatitis C patients treated with different doses of consensus interferon. Hepatol Res 2002; 24: 236-44.

8. Clarkson PM, Thmpson HS. Antioxidants: what role do they play in physical activity and health? Am J Clin Nutr 2000; 72(2 suppl): 637s-46s.

9. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186: 421-431.

10. Eboumboua C, Steghensb JP, Abdallahia OMS, Mirghanic A, Galliand P, Kappelb AV, Qurashie A, Ghariba B, Reggi MD. (2005): Circulating markers of oxidative stress and liver fibrosis in Sudanese subjects at risk of schistosomiasis and hepatitis. Acta Tropica 1990; 94(2): 99-106.

11. El-Sokkary GH, Omar HM, Hassanein AMM, Cuzzocrea S, Reiter RJ. Melatonin reduces oxidative damage and increases survival of mice infected with Schistosoma mansoni. Free Radical Biology and Medicine 2002; 32(4): 319-332.

12. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87(10): 4068-71.

13. Feese MD, Tamada T, Kato Y, Maeda Y, Matsumoto A. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci 2004; 101(7): 1816-1821.

14. Fox N, Priestley, G, Papayannopoulou T, Kaushansky K. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 2002; 110(3): 389-394.

15. Freni MA, Spadaro A, Ajello A, Barbaro E, Scaffidi M, Alessi N, Resta ML, Ferrau O. Serum thrombopoietin in chronic liver disease: relation to severity of the disease and spleen size. Hepatogastroentrology 2002; 49: 1382-1385.

16. Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol 2006; 22(3): 254-262.

17. George JN. Platelets. Lancet 2000; 355: 1531-9.

18. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, Testa E, Podesta E, Chiarbonello B, Polegato S, Mamone M, Testa R. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis c virus infection. Am J Gastroenterology 2003; 98: 2516-2520.

19. Giannini EG. Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23(8): 1055-65.

20. Gouin-Thibault I, Cassinat B, Chomienne C, Rain JD, Najean Y, Schlageter MH. Is the thrombopoietin assay useful for differential diagnosis of thrombocytopenia? Analysis of a cohort of 160 patients with thrombocytopenia and defined platelet life sspan. Clin Chem 2001; 47(9): 1660-5.

21. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44(5): 754-8.

22. Hidaka H, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002; 23: 265-73.

23. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician 2006; 74(5): 767-776.

24. Hobisch-Hagen P, Jelkmann W, Mayr A, Wiedermann FJ, Fries D, Herold M, Klingler A, Schobersberger W. Low platelet count and elevated serum thrombopoietin after severe trauma. Eur J Haematol 2000; 64(3): 157-63.

25. Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, Miyazaki H, Asakura H. Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol. Hepatol 1998; 13(9): 907-913.

26. Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, Miyazaki H, Asakura H. Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol 1998; 13(9): 907-913.

27. Ishikawa T, Ichida T, Sugahara S, Yamagiwa S, Matsuda Y, Uehara K, Kato T, Miyazaki H, Asakura H. (2002): Thrombopoietin receptor (c-Mpl) is constitutively expressed on platelets of patients with liver cirrhosis, and correlates with its disease progression. Hepatol Res 2002; 23(2): 115-121.

28. Itoh R, Katayama N, Kato, T, Mahmud N, Masuya M, Ohishi K, Minami N, Miyazaki H, Shiku H. Activity of the ligand for c-mpl, thrombopoietin, in early haemopoiesis. British Journal of Hematology 1996; 94(2): 228-235.

29. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. European Journal of Gastroenterology & Hematology 2001; 13: 791-801.

30. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M. A Role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 1267-1276.

31. Katalinic V, Modun D, Music TI, Boban M. Gender differences in antioxidant capacity of rat tissues determined by 2,2V-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS). Comparative Biochemistry and Physiology, Part C. 2005; 140: 47–52.

32. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. The American Journal of Gastroenterology 1999; 94(7): 1918-1922.

33. Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatology Research 2006; 34: 65-73.

34. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001; 54: 356-361.

35. Korenag M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases ROS production. JBC 2005; 8: 1-14.

36. Koruk M, Onuk MD, Akcay F, Savas MC. (2002): Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroentrology 2002; 49: 1645-1648.

37. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Annual of Clinical &Laboratory Science 2002; 34(1): 57-62.

38. Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E, Ahmet S. (2006): Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006; 4(1): 25-31.

39. Levin J. Thrombopoietin - clinically realized? The New England Journal of Medicine 1999; 336(6): 434-436.

40. Levine SP. Thrombocytopenia: pathophysiology and classification. In: Wintrobe’s Clinical Hematology. Lee GR, Foerster J, Lukins J, Parashskevas F, Gareer JP, Rodgers GM. (eds). Williams & Wilkins, Walnut Street, Philadelphia, USA. 1999: 1579-1584.

41. Li Q, Sun GZ, Wang BE, Jia JD, Ma H, Wei YX, Cong YL, Shen J. The relationship among the counts of platelet, thrombopoietin and spleen index in patients with liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2004; 12(4): 210-2.

42. Linden HM, Kaushansky K. The glycan domain of thrombopoietin (TPO) acts in trans to enhance secretion of the hormone and other cytokines. J Biol Chem 2002; 277(38): 35240-35247.

43. Ljubuncic P, Tanne Z, Bomzon A. Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease. Gut 2000; 47(5): 710-716.

44. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127: 285-28.

45. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(6): 1009-31.

46. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis c virus-associated hepatocarcinogenesis. Cancer Research 2001; 61: 4365-4370.

47. Muto T, Feese MD, Shimada Y, Kudou Y, Okamoto T, Ozawa T. Functional analysis of the C-terminal region of recombinant human thrombopoietin. J Biol Chem 2000; 275(16): 12090-12094.

48. Ngaiza JR, Doenhoff MJ. Blood platelets and schistosome egg excretion. Proc Soc Exp Biol Med 1990; 193(1): 73-79.

49. Notas G, Miliaraki N, Kampa M, Dimoulios F, Matrella E, Hatzidakis A, Castanas E, Kouroumalis E. Patients with primary biliary cirrhosis have increased serum total antioxidant capacity measured with the crocin bleaching assay. World J Gastroenterol 2005; 11(27): 4194-4198.

50. Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 2000; 99(3): 207-214.

51. Paradis A, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997; 26: 135-142.

52. Pemberton PW, Aboutwerat A, Smith A, Burrows PC, McMahon RFT, Warnes TW. Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis? Biochim Biophys Acta 2004; 1689(3): 182-189.

53. Pinto AG, Namyslowski J, Pandya P. Severe thrombocytopenia due to hypersplenism successfully treated with partial splenic embolization in preoperative management. Southern Medical Journal 2005; 98(4): 281-283.

54. Prakash S, Joshi YK. Assessment of micronutrient antioxidants, total antioxidant capacity and lipid peroxidation levels in liver cirrhosis. Asia Pac J Clin Nutr 2004; 13(Suppl): S110.

55. Romero FJ, Bosch-Morell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J. Lipid per oxidation products and antioxidants in human disease. Environ Health Perspect 1998; 106 Suppl 5: 1229-34.

56. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radical Biology & Medicine 1998; 25(9): 993-997.

57. Sampey BP, Korourian S, Ronis MJ, Badger TM, Petersen DR. Immunohistochemical characterization of hepatic malondialdehyde and 4-hydroxynonenal modified proteins during early stages of ethanol-induced liver injury. Alcoholism: Clinical and Experimental Research 2003; 27(6): 1015-1022.

58. Saricam T, Kircali B, Koken T. Assessment of lipid peroxidation and antioxidant capacity in non-alcoholic fatty liver disease. Turk J Gastroenterol 2005; 16(2): 65-70.

59. Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 1999; 93(9): 2928-2935.

60. Sayed AA, Cook SK, Williams DL. Redox balance mechanisms in schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. The Journal of Biological Chemistry 2006; 281(25): 17001-17010.

61. Sekiguchi T, Nagamine T, Takagi H, Mori M. Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients with accompanying hepatitis C. World J Gastroenterol 2006; 12(8): 1205-10.

62. Singh R, Singh RK, Singh RK, Tripathi AK, Cornflissen G, Schwartzkopff O, Otsuka K, Halberg F. Chronomics of circulating plasma lipid peroxides and anti-oxidant enzymes and other related molecules in cirrhosis of liver. Biomedicine & Pharmacotherapy 2005; 59: S229-S235.

63. Souza MR, Aguiar LA, Goto JM, Carvente CT, Toledo CF, Borges DR. Thrombopoietin serum levels don’t correlate with thrombocytopenia in hepatic schistosomiasis. Liver 2002; 22: 127-129.

64. Stanley RG, Ngaiza JR, Atieno E, Jell G, Francklow K, Jackson CL, Parry H, Doenhoff MJ. Immune-dependent thrombocytopenia in mice infected with Schistosoma mansoni. Parasitology 2003; 126(Pt 3): 225-9.

65. Sungaran R, Chisholm QT, Markovic B, Khachigian LM, Tanaka Y, Chong BH. The role of platelet a-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood 2000; 95(10): 3094-3101.

66. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica 1999; 84: 158-166.

67. Wendling F, Vainchenker W. Thrombopoietin and its receptor. European Cytokine Network, 1998; 9(3): 221-31.

68. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002; 17: 6-10.

69. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. The American Journal of Gastroenterology 2002; 97(10): 2639-2634.